About DANDRITE

Nordic EMBL Partnership and DANDRITE

The Nordic EMBL Partnership is a joint venture between the European Molecular Biology Laboratory (EMBL) and the Universities of Helsinki/Finland, Oslo/Norway, Umea/Sweden and Aarhus/Denmark. The four nodes of the partnership (FIMM/Helsinki, NCMM/Oslo, MIMS/Umea, and DANDRITE/Aarhus) adhere to the EMBL model for research organization, training and evaluation, and are primarily organized by group leader programs. The partnership provides joint access to research infrastructures, including databases, facilities and instrumentation, as well as to clinical materials, networks and training activities.

DANDRITE is established with financial support from the Lundbeck Foundation and is hosted by Aarhus University, an international, top-ranking university. The research scope is on integrative/systems neuroscience and molecular mechanisms of inter- and intracellular networks and molecular trafficking that defines neurobiology, and how these mechanisms are linked and operate in the healthy brain, and how they are altered and can be targeted in brain disorders. Translational studies have a particular focus on neurodegenerative, psychiatric and neurological disorders.

DANDRITE is embedded in a vibrant NeuroCampus Aarhus research community at Aarhus University and Aarhus University Hospital and encompasses internationally leading research centers and infrastructures in genetics, molecular and clinical medicine, bioimaging, cognitive neuroscience, transgenic animal models, biochemistry, biophysics, structural biology, nanoscience, and engineering. There are long-standing traditions in studies of for example membrane proteins, molecular neuroscience, brain function and imaging, and more recently also oriented towards circuitry and behavioral models.

More information about DANDRITE: https://dandrite.au.dk/info-for-staff-visitors

Department of Biomedicine

At the Department of Biomedicine, we conduct research in human biology and diseases and educate students within these fields. The department also provides formalized consultancy assignments on matters of pharmacotherapy.

The department was formed in 2011 by the merger of six biomedical departments. Our aim is to gain a better understanding of diseases at the molecular and cellular level - by bridging the gap between natural science and clinical medicine and by using the results for improved diagnostics, counseling and patient treatment.

More information about the Department of Biomedicine: https://biomed.au.dk